Woburn, MA, USA
December 21, 2017
Yield10 Bioscience, Inc. (NASDAQ:YTEN) today announced the closing of an underwritten public offering of units for gross proceeds of $14.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. Both existing investors, including 40% shareholder Jack W. Schuler, and new institutional investors participated in the offering.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), is sole book-running manager in connection with the offering.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-221283), which was declared effective by the United States Securities and Exchange Commission on December 18, 2017, and an additional registration statement filed pursuant to Rule 462(b) (File No. 333-222147).
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering has been filed by Yield10 Bioscience with the SEC. Copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.
Topics
Species
